The CHARM Trial of Adalimumab in Crohn's Disease.
作者信息
Colombel Jean-Frédéric
机构信息
Centre Hospitalier Universitaire Lille, France.
出版信息
Gastroenterol Hepatol (N Y). 2006 Jul;2(7):486-488.
Abstract
摘要
相似文献
1
The CHARM Trial of Adalimumab in Crohn's Disease.阿达木单抗治疗克罗恩病的CHARM试验
Gastroenterol Hepatol (N Y). 2006 Jul;2(7):486-488.
2
Effects of adalimumab maintenance therapy on health-related quality of life of patients with Crohn's disease: patient-reported outcomes of the CHARM trial.阿达木单抗维持治疗对克罗恩病患者健康相关生活质量的影响：CHARM试验的患者报告结局
Am J Gastroenterol. 2008 Dec;103(12):3132-41. doi: 10.1111/j.1572-0241.2008.02175.x. Epub 2008 Oct 3.
3
Cost-effectiveness of adalimumab for the maintenance of remission in patients with Crohn's disease.阿达木单抗用于维持克罗恩病缓解的成本效益。
Eur J Gastroenterol Hepatol. 2009 Nov;21(11):1302-9. doi: 10.1097/MEG.0b013e32832a8d71.
4
Comparison of two adalimumab treatment schedule strategies for moderate-to-severe Crohn's disease: results from the CHARM trial.两种阿达木单抗治疗方案用于中重度克罗恩病的比较：CHARM试验结果
Am J Gastroenterol. 2009 May;104(5):1170-9. doi: 10.1038/ajg.2009.59. Epub 2009 Apr 7.
5
Adalimumab sustains steroid-free remission after 3 years of therapy for Crohn's disease.阿达木单抗治疗克罗恩病 3 年后可维持无激素缓解。
Aliment Pharmacol Ther. 2011 Aug;34(3):306-17. doi: 10.1111/j.1365-2036.2011.04717.x. Epub 2011 Jun 5.
6
Number needed to treat and cost per remitter for biologic treatments of Crohn's disease in Japan.日本克罗恩病生物治疗的需要治疗人数和每位缓解者的成本。
J Med Econ. 2020 Jan;23(1):80-85. doi: 10.1080/13696998.2019.1642900. Epub 2019 Aug 13.
7
Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial.阿达木单抗用于维持克罗恩病患者的临床反应和缓解：CHARM试验
Gastroenterology. 2007 Jan;132(1):52-65. doi: 10.1053/j.gastro.2006.11.041. Epub 2006 Nov 29.
8
Effect of adalimumab on clinical laboratory parameters in patients with Crohn's disease: results from the CHARM trial.阿达木单抗对克罗恩病患者临床实验室参数的影响：CHARM 试验结果。
Inflamm Bowel Dis. 2012 May;18(5):818-25. doi: 10.1002/ibd.21836. Epub 2011 Sep 1.
9
Adalimumab sustains clinical remission and overall clinical benefit after 2 years of therapy for Crohn's disease.阿达木单抗治疗克罗恩病 2 年后持续缓解临床症状并带来整体临床获益。
Aliment Pharmacol Ther. 2010 Jun;31(12):1296-309. doi: 10.1111/j.1365-2036.2010.04304.x. Epub 2010 Mar 18.
10
Adalimumab: in Crohn's disease.阿达木单抗：用于克罗恩病。
BioDrugs. 2007;21(2):125-32; discussion 133-4. doi: 10.2165/00063030-200721020-00007.
引用本文的文献
1
Under the Umbrella of Clinical Pharmacology: Inflammatory Bowel Disease, Infliximab and Adalimumab, and a Bridge to an Era of Biosimilars.在临床药理学的框架下：炎症性肠病、英夫利昔单抗和阿达木单抗，以及通往生物类似药时代的桥梁。
Pharmaceutics. 2022 Aug 24;14(9):1766. doi: 10.3390/pharmaceutics14091766.
2
Heterogeneity in pharmacological treatment and outcomes in Crohn's disease patients in Catalonia: a population-based observational study.加泰罗尼亚地区克罗恩病患者药物治疗和结局的异质性：一项基于人群的观察性研究。
Ann Med. 2022 Dec;54(1):1255-1264. doi: 10.1080/07853890.2022.2069851.
3
Adalimumab for maintenance of remission in Crohn's disease.阿达木单抗用于维持克罗恩病的缓解状态。
Cochrane Database Syst Rev. 2020 May 16;5(5):CD012877. doi: 10.1002/14651858.CD012877.pub2.
4
A Saudi Gastroenterology association position statement on the use of tumor necrosis factor-alfa antagonists for the treatment of inflammatory bowel disease.沙特胃肠病学协会关于使用肿瘤坏死因子-α拮抗剂治疗炎症性肠病的立场声明。
Saudi J Gastroenterol. 2015 Jul-Aug;21(4):185-97. doi: 10.4103/1319-3767.161635.
本文引用的文献
1
Emerging biological treatments in inflammatory bowel diseases.炎症性肠病的新兴生物治疗方法。
Dig Dis. 2006;24(1-2):131-6. doi: 10.1159/000090316.
2
Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial.人抗肿瘤坏死因子单克隆抗体（阿达木单抗）治疗克罗恩病：CLASSIC - I试验
Gastroenterology. 2006 Feb;130(2):323-33; quiz 591. doi: 10.1053/j.gastro.2005.11.030.
3
Autoimmunity and anti-TNF-alpha agents.自身免疫与抗肿瘤坏死因子-α制剂
Ann N Y Acad Sci. 2005 Jun;1051:559-69. doi: 10.1196/annals.1361.100.
Zotero 插件